Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial

• Published in: Schizophrenia research Vol. 107; no. 2; pp. 206 - 212
• Main Authors: Akhondzadeh, Shahin, Mohammadi, Neyousha, Noroozian, Maryam, Karamghadiri, Naregs, Ghoreishi, Aboulfazl, Jamshidi, Amir-Hossein, Forghani, Saeedeh
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.02.2009; Elsevier
• Subjects: 5-HT3; Adult; Adult and adolescent clinical studies; Antipsychotic Agents - administration & dosage; Antipsychotic Agents - adverse effects; Biological and medical sciences; Case-Control Studies; Chronic Disease; Cognition Disorders - diagnosis; Cognition Disorders - drug therapy; Cognition Disorders - psychology; Cognitive impairments; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Medical sciences; Neuropsychological Tests; Ondansetron; Ondansetron - administration & dosage; Ondansetron - adverse effects; Psychiatric Status Rating Scales; Psychiatry; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychoses; Risperidone - administration & dosage; Schizophrenia; Schizophrenia - drug therapy; Schizophrenic Psychology; Serotonin Antagonists - administration & dosage; Serotonin Antagonists - adverse effects; Young Adult; Schizophrenia; Cognitive impairments; Ondansetron; 5-HT3; Psychosis; Human; Cognitive disorder; Serotonin antagonist; 5-HT3 Serotonine receptor; Double blind study; Controlled therapeutic trial; Antiemetic

It is well documented that 5-hydroxytryptamine3 (5-HT3) receptors are involved in the pathogenesis of schizophrenia and cognitive impairment. The purpose of this study was to assess the efficacy of ondansetron, a 5-HT3 receptor antagonist as an adjuvant agent in the treatment of chronic schizophreni...